Opicapone (ONGENTYS) approved by FDA in April 2020 for the treatment of patients with Parkinson’s disease experiencing "off" episodes. It is a once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase (COMT) inhibitor. Opicapone contains 5-phenyl-1,2,4-oxadiazole moiety in its backbone. We have made a set of Building Blocks, which contain such part – the perfect start for your research!